var data={"title":"Acute palmoplantar eczema (dyshidrotic eczema)","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Acute palmoplantar eczema (dyshidrotic eczema)</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/contributors\" class=\"contributor contributor_credentials\">David R Adams, MD, PharmD</a></dd><dd><a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/contributors\" class=\"contributor contributor_credentials\">James G Marks, Jr, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/contributors\" class=\"contributor contributor_credentials\">Joseph Fowler, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/contributors\" class=\"contributor contributor_credentials\">Rosamaria Corona, MD, DSc</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;May 30, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H26544681\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Acute palmoplantar eczema (more popularly known as dyshidrotic eczema or pompholyx) is an intensely pruritic, vesicular eruption affecting the palms, soles, or both [<a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/abstract/1,2\" class=\"abstract_t\">1,2</a>]. It is characterized by deep-seated lesions ranging from small vesicles to large tense bullae clinically and by spongiotic vesicles histologically. Recurrence is common and patients typically experience frequent episodes for months or years. </p><p>This topic will discuss the pathogenesis, clinical presentation, diagnosis, and management of dyshidrotic eczema. Other forms of eczema involving the hands, including irritant and allergic contact dermatitis and atopic dermatitis, are discussed separately. (See <a href=\"topic.htm?path=irritant-contact-dermatitis-in-adults\" class=\"medical medical_review\">&quot;Irritant contact dermatitis in adults&quot;</a> and <a href=\"topic.htm?path=clinical-features-and-diagnosis-of-allergic-contact-dermatitis\" class=\"medical medical_review\">&quot;Clinical features and diagnosis of allergic contact dermatitis&quot;</a> and <a href=\"topic.htm?path=management-of-allergic-contact-dermatitis\" class=\"medical medical_review\">&quot;Management of allergic contact dermatitis&quot;</a> and <a href=\"topic.htm?path=atopic-dermatitis-eczema-pathogenesis-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Atopic dermatitis (eczema): Pathogenesis, clinical manifestations, and diagnosis&quot;</a> and <a href=\"topic.htm?path=treatment-of-atopic-dermatitis-eczema\" class=\"medical medical_review\">&quot;Treatment of atopic dermatitis (eczema)&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H26006232\"><span class=\"h1\">TERMINOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The terminology for acute palmoplantar eczema is confusing. The term &quot;dyshidrosis&quot; was coined in 1873 to describe a blistering disease of the palms and soles that was believed to be a disorder of the sweat glands [<a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/abstract/3\" class=\"abstract_t\">3</a>]. It is now accepted that the sweat glands are not involved in the pathogenesis [<a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/abstract/4,5\" class=\"abstract_t\">4,5</a>]. However, the term &quot;dyshidrotic eczema&quot; continues to be used.</p><p>Other terms for acute palmoplantar eczema include pompholyx, dyshidrosis, vesicular palmoplantar eczema, acute and recurrent vesicular hand dermatitis, cheiropompholyx (affecting the hands), or podopompholyx (affecting the feet). These terms do <strong>not</strong> represent a specific diagnosis, but rather a morphologic pattern of <span class=\"nowrap\">hand/foot</span> eczema that can occur with irritant contact, allergic contact, or endogenous eczema.</p><p class=\"headingAnchor\" id=\"H26544689\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The prevalence of dyshidrotic eczema, including mild and severe forms of dyshidrotic eczema, in the general population is unknown. In occupational or clinical settings, dyshidrotic eczema accounts for 5 to 20 percent of all cases of hand dermatitis [<a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/abstract/6,7\" class=\"abstract_t\">6,7</a>]. It occurs most commonly in young adults and equally among males and females. Risk factors for dyshidrotic eczema include history of atopic dermatitis and exposure to contact allergens or irritants [<a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/abstract/8-10\" class=\"abstract_t\">8-10</a>]. A rare autosomal dominant form of dyshidrotic eczema has been described [<a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/abstract/11\" class=\"abstract_t\">11</a>].</p><p class=\"headingAnchor\" id=\"H26544705\"><span class=\"h1\">ETIOLOGY AND PATHOGENESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The cause of dyshidrotic eczema is unknown, but it is probably multifactorial. Although in most cases, a causative or predisposing factor cannot be identified, factors that have been associated with the development of dyshidrotic eczema include: </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>History of atopic dermatitis [<a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/abstract/10,12\" class=\"abstract_t\">10,12</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Exposure to contact allergens, particularly metals [<a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/abstract/9,10,13\" class=\"abstract_t\">9,10,13</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Exposure to contact irritants (eg, metalworking fluids) [<a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/abstract/8\" class=\"abstract_t\">8</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Systemic exposure to contact allergens (eg, ingestion of nickel or cobalt) [<a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/abstract/14\" class=\"abstract_t\">14</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Dermatophyte infection at a distant site (id reaction) [<a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/abstract/12\" class=\"abstract_t\">12</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Intravenous <a href=\"topic.htm?path=immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information\" class=\"drug drug_general\">immune globulin</a> [<a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/abstract/13,15-19\" class=\"abstract_t\">13,15-19</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hyperhidrosis [<a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/abstract/10\" class=\"abstract_t\">10</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Smoking [<a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/abstract/20\" class=\"abstract_t\">20</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Exposure to ultraviolet (UV) radiation [<a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/abstract/21\" class=\"abstract_t\">21</a>]</p><p/><p class=\"headingAnchor\" id=\"H26544713\"><span class=\"h1\">CLINICAL PRESENTATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Episodes of dyshidrotic eczema often start with pruritus followed by a sudden eruption of intensely pruritic vesicles on the palms (<a href=\"image.htm?imageKey=DERM%2F83056\" class=\"graphic graphic_picture graphicRef83056 \">picture 1D</a>), lateral and dorsal aspects of the fingers (<a href=\"image.htm?imageKey=DERM%2F112980\" class=\"graphic graphic_picture graphicRef112980 \">picture 1C</a>), or soles. In 70 to 80 percent of patients, only the hands are involved [<a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/abstract/13\" class=\"abstract_t\">13</a>]. The palms and soles are usually symmetrically involved, but in mild cases, vesicles develop only on the lateral aspect of fingers (<a href=\"image.htm?imageKey=DERM%2F82781%7EDERM%2F82783%7EDERM%2F112980\" class=\"graphic graphic_picture graphicRef82781 graphicRef82783 graphicRef112980 \">picture 1A-C</a>). The vesicles are typically deep-seated and multilocular (&quot;tapioca or sago pudding&quot; lesions); they may coalesce into large bullae (<a href=\"image.htm?imageKey=DERM%2F83007\" class=\"graphic graphic_picture graphicRef83007 \">picture 2A</a>). In some patients, symptoms may be severe enough to interfere with occupational duties and daily activities (<a href=\"image.htm?imageKey=DERM%2F83006\" class=\"graphic graphic_picture graphicRef83006 \">picture 2B</a>). </p><p>Vesicles and bullae persist for several weeks, desiccate, and resolve with desquamation (<a href=\"image.htm?imageKey=DERM%2F82782\" class=\"graphic graphic_picture graphicRef82782 \">picture 3</a>) [<a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/abstract/1,3\" class=\"abstract_t\">1,3</a>]. Frequent relapses may result in chronic hand dermatitis, characterized by red, lichenified, and scaling patches or plaques with fissures. Severe episodes can affect the nail matrix and produce dystrophic nail changes such as horizontal ridging and color changes (<a href=\"image.htm?imageKey=DERM%2F82784\" class=\"graphic graphic_picture graphicRef82784 \">picture 1E</a>). Secondary infection, usually with <em>Staphylococcus aureus</em>, may occur. </p><p>Episodes may recur at intervals of three to four weeks for months or years and are more common in warm weather. In some patients, flares may be associated with emotional or physical stress but most often they occur in the absence of an identifiable trigger.</p><p class=\"headingAnchor\" id=\"H26544729\"><span class=\"h1\">DIAGNOSIS</span></p><p class=\"headingAnchor\" id=\"H18792269\"><span class=\"h2\">Clinical diagnosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnosis of dyshidrotic dermatitis is usually made based upon clinical findings, symptoms, and history:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Tense, deep-seated vesicles or bullae localized on the palms and soles and often on the lateral aspect of the fingers (<a href=\"image.htm?imageKey=DERM%2F83056%7EDERM%2F112980\" class=\"graphic graphic_picture graphicRef83056 graphicRef112980 \">picture 1C-D</a>)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Intense pruritus</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Acute onset</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>History of recurrence</p><p/><p>In mild cases, tiny vesicles may be seen only on the lateral aspect of fingers (<a href=\"image.htm?imageKey=DERM%2F83010\" class=\"graphic graphic_picture graphicRef83010 \">picture 1G</a>).</p><p class=\"headingAnchor\" id=\"H18792277\"><span class=\"h2\">Histopathology</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A skin biopsy for histopathologic examination is rarely needed. Potential indications for skin biopsy include lack of response to treatment and exclusion of other conditions in the differential diagnosis (eg, psoriasis or palmoplantar pustulosis). If a skin biopsy is performed, periodic acid-Schiff (PAS) staining for fungal elements may be useful in excluding a fungal infection. (See <a href=\"#H26544737\" class=\"local\">'Differential diagnosis'</a> below.) </p><p>The histologic features of dyshidrotic eczema depend upon the stage (acute or chronic) of the disease: </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The acute form is characterized by intraepidermal spongiotic vesicles or bullae that do not involve the intraepidermal portion of the eccrine sweat duct (acrosyringium). A sparse, superficial perivascular infiltrate of lymphocytes is usually present. The epidermal thickness is normal and the thick stratum corneum of acral skin is intact. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In chronic cases, there is a predominance of parakeratosis and acanthosis with minimal or no spongiosis and a dermal lymphocytic infiltrate. </p><p/><p class=\"headingAnchor\" id=\"H18792310\"><span class=\"h2\">Patch testing</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patch testing is not helpful in making the diagnosis of dyshidrotic eczema. However, it is often performed by dermatologists to determine whether there is a component of allergic contact dermatitis, in which case avoidance of the allergen is an important part of management, and may be warranted in patients who do not respond to initial therapy [<a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/abstract/1,3\" class=\"abstract_t\">1,3</a>]. (See <a href=\"topic.htm?path=patch-testing\" class=\"medical medical_review\">&quot;Patch testing&quot;</a> and <a href=\"topic.htm?path=management-of-allergic-contact-dermatitis#H6508906\" class=\"medical medical_review\">&quot;Management of allergic contact dermatitis&quot;, section on 'Avoidance'</a>.)</p><p class=\"headingAnchor\" id=\"H26544737\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The differential diagnosis of dyshidrotic eczema includes the following inflammatory and infectious vesicobullous skin diseases [<a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/abstract/1,3\" class=\"abstract_t\">1,3</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Allergic contact dermatitis</strong> &ndash; Allergic contact dermatitis may be clinically indistinguishable from dyshidrotic eczema (<a href=\"image.htm?imageKey=DERM%2F82993%7EDERM%2F83192\" class=\"graphic graphic_picture graphicRef82993 graphicRef83192 \">picture 4A-B</a>). The correct diagnosis is based upon the assessment of allergen exposure and results of patch testing. (See <a href=\"topic.htm?path=clinical-features-and-diagnosis-of-allergic-contact-dermatitis#H1646554\" class=\"medical medical_review\">&quot;Clinical features and diagnosis of allergic contact dermatitis&quot;, section on 'Diagnosis'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Bullous tinea</strong> &ndash; Bullous tinea occurs more often on the feet than on the hands and is usually unilateral (<a href=\"image.htm?imageKey=PC%2F54214%7EDERM%2F82787\" class=\"graphic graphic_picture graphicRef54214 graphicRef82787 \">picture 5A-B</a>). Potassium hydroxide (KOH) microscopic examination of scrapings from the lesions reveals fungal elements. (See <a href=\"topic.htm?path=dermatophyte-tinea-infections#H15\" class=\"medical medical_review\">&quot;Dermatophyte (tinea) infections&quot;, section on 'Tinea pedis'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Irritant contact dermatitis </strong>&ndash; Irritant contact dermatitis usually involves the dorsal aspect of the hands and web spaces (<a href=\"image.htm?imageKey=DERM%2F50299%7EDERM%2F59959\" class=\"graphic graphic_picture graphicRef50299 graphicRef59959 \">picture 6A-B</a>). Patients often report a history of irritant exposure. (See <a href=\"topic.htm?path=irritant-contact-dermatitis-in-adults\" class=\"medical medical_review\">&quot;Irritant contact dermatitis in adults&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Atopic hand dermatitis</strong> &ndash; Atopic hand dermatitis commonly involves the dorsum of the hands. Patients report a history of atopic dermatitis, seasonal allergies, or asthma and may present with eczema lesions or lichenification involving flexural areas (ie, antecubital and popliteal fossae) (<a href=\"image.htm?imageKey=DERM%2F82881\" class=\"graphic graphic_picture graphicRef82881 \">picture 7</a>). (See <a href=\"topic.htm?path=atopic-dermatitis-eczema-pathogenesis-clinical-manifestations-and-diagnosis#H12\" class=\"medical medical_review\">&quot;Atopic dermatitis (eczema): Pathogenesis, clinical manifestations, and diagnosis&quot;, section on 'Diagnosis'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Dermatophytid (id) reaction</strong> &ndash; A dermatophytid reaction is a secondary pruritic, papulovesicular eruption that may occur on the palms in association with a dermatophyte infection at a distant site (eg, on the scalp or foot) (<a href=\"image.htm?imageKey=DERM%2F52664\" class=\"graphic graphic_picture graphicRef52664 \">picture 8</a>). A complete skin examination and a KOH preparation of scrapings from suspicious lesions are necessary to confirm the diagnosis. (See <a href=\"topic.htm?path=dermatophyte-tinea-infections#H4733135\" class=\"medical medical_review\">&quot;Dermatophyte (tinea) infections&quot;, section on 'Dermatophytid (id) reactions'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Herpetic infection</strong> &ndash; Herpetic lesions present as grouped vesicles on a red base, are more often painful than pruritic, and usually unilateral (<a href=\"image.htm?imageKey=ID%2F52029\" class=\"graphic graphic_picture graphicRef52029 \">picture 9</a>). The diagnosis can be made by viral culture, immunofluorescence staining, polymerase chain reaction, or Tzanck smear. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-herpes-simplex-virus-type-1-infection#H25\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of herpes simplex virus type 1 infection&quot;, section on 'Diagnosis'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Palmoplantar pustulosis </strong>&ndash; Palmoplantar pustulosis may have an early vesicular stage, but pustules usually develop in a few days (<a href=\"image.htm?imageKey=DERM%2F62582%7EDERM%2F82843\" class=\"graphic graphic_picture graphicRef62582 graphicRef82843 \">picture 10A-B</a>). In 8 to 10 days the pustules change their color to dark brown, become dry, and desquamate (<a href=\"image.htm?imageKey=DERM%2F82842\" class=\"graphic graphic_picture graphicRef82842 \">picture 11</a>). (See <a href=\"topic.htm?path=neutrophilic-dermatoses#H25\" class=\"medical medical_review\">&quot;Neutrophilic dermatoses&quot;, section on 'Palmoplantar pustulosis'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Autoimmune bullous diseases</strong> &ndash; Bullous pemphigoid and pemphigus vulgaris may rarely present as localized disease involving the hands or feet (<a href=\"image.htm?imageKey=DERM%2F50357\" class=\"graphic graphic_picture graphicRef50357 \">picture 12</a>). The history reflects a longer and unremitting course. Biopsy for routine histology, direct immunofluorescence, and serologic testing for specific autoantibodies provide the correct diagnosis. (See <a href=\"topic.htm?path=clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid#H20007006\" class=\"medical medical_review\">&quot;Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid&quot;, section on 'Diagnosis'</a> and <a href=\"topic.htm?path=pathogenesis-clinical-manifestations-and-diagnosis-of-pemphigus#H458196\" class=\"medical medical_review\">&quot;Pathogenesis, clinical manifestations, and diagnosis of pemphigus&quot;, section on 'Diagnosis'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H20269882\"><span class=\"h1\">CLINICAL COURSE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Dyshidrotic eczema is a recurrent disease. Patients typically experience frequent attacks of vesicular dermatitis for many years. Episodes tend to occur less frequently with age and most patients eventually go into complete remission [<a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/abstract/22\" class=\"abstract_t\">22</a>].</p><p class=\"headingAnchor\" id=\"H26544808\"><span class=\"h1\">MANAGEMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The management of dyshidrotic eczema involves the identification and avoidance of causative or exacerbating factors, treatment of skin inflammation, and adoption of skin care measures to reduce skin irritation. Dyshidrotic eczema has a tendency to spontaneously resolve over several weeks. However, treatment is required for most patients who present with complaints of pruritus or other symptoms. The approach to treatment is guided by the severity of the disease.</p><p class=\"headingAnchor\" id=\"H20269116\"><span class=\"h2\">Assessment of severity</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The severity of dyshidrotic eczema is generally assessed subjectively. A scoring tool called the dyshidrotic eczema area and severity index (DASI), based upon the number of vesicles, intensity of erythema, desquamation, and itch, was designed for use in clinical trials but is not routinely used in clinical practice [<a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/abstract/23\" class=\"abstract_t\">23</a>]. </p><p>We consider dyshidrotic eczema to be mild to moderate if it does not involve the entire palmar or plantar surface, presents as a few crops of vesicles or scattered small vesicles with absent or modest erythema (<a href=\"image.htm?imageKey=DERM%2F82784%7EDERM%2F83056%7EDERM%2F83053%7EDERM%2F82781\" class=\"graphic graphic_picture graphicRef82784 graphicRef83056 graphicRef83053 graphicRef82781 \">picture 1A, 1D-F</a>), and the patient does not complain of intolerable pruritus, burning, or pain.</p><p>We consider dyshidrotic eczema to be severe if large vesicles or bullae are disabling (<a href=\"image.htm?imageKey=DERM%2F83007%7EDERM%2F83006%7EDERM%2F83055\" class=\"graphic graphic_picture graphicRef83007 graphicRef83006 graphicRef83055 \">picture 2A-C</a>) (ie, prevent walking or use of the hands) or if&nbsp;it is intensely painful or pruritic (regardless of the size of the lesions).</p><p class=\"headingAnchor\" id=\"H16212203\"><span class=\"h2\">General measures</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In clinical experience, avoidance of irritants or exacerbating factors is beneficial for most patients with dyshidrotic eczema. General skin care measures aimed at reducing skin irritation and restoring the skin barrier include [<a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/abstract/24\" class=\"abstract_t\">24</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Using lukewarm water and soap-free cleansers to wash hands</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Drying hands thoroughly after washing</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Applying emollients (eg, petroleum jelly) immediately after hand drying and as often as possible </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Wearing cotton gloves under vinyl or other nonlatex gloves when performing wet work</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Removing rings and watches and bracelets before wet work</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Wearing protective gloves in cold weather </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Wearing task-specific gloves for frictional exposures (eg, gardening, carpentry)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Avoiding exposure to irritants (eg, detergents, solvents, hair lotions or dyes, acidic foods [eg, citrus fruit]) </p><p/><p>In clinical practice, astringent solutions such as aluminum subacetate (Burow's solution) or <a href=\"topic.htm?path=witch-hazel-drug-information\" class=\"drug drug_general\">witch hazel</a> are used for wet, weeping skin. Hands or feet are soaked in the solution for 15 minutes two to four times per day. Large bullae may be drained or aspirated using a sterile syringe to reduce pain and prevent spontaneous rupture with risk of local infection.</p><p class=\"headingAnchor\" id=\"H16212111\"><span class=\"h2\">Mild to moderate disease</span></p><p class=\"headingAnchor\" id=\"H15309892\"><span class=\"h3\">Topical corticosteroids</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For patients with mild to moderate dyshidrotic eczema (<a href=\"image.htm?imageKey=DERM%2F82784%7EDERM%2F83056%7EDERM%2F83053%7EDERM%2F82781\" class=\"graphic graphic_picture graphicRef82784 graphicRef83056 graphicRef83053 graphicRef82781 \">picture 1A, 1D-F</a>) that has not responded to general measures, we suggest super high potency or high potency topical corticosteroids (group one to three (<a href=\"image.htm?imageKey=DERM%2F62402\" class=\"graphic graphic_table graphicRef62402 \">table 1</a>)) rather than calcineurin inhibitors, which are approximately equivalent to moderate potency corticosteroids. (See <a href=\"#H20269116\" class=\"local\">'Assessment of severity'</a> above and <a href=\"#H16212203\" class=\"local\">'General measures'</a> above.)</p><p>Topical corticosteroids are applied twice daily for two to four weeks. Ointments generally are preferred to other vehicles (creams, solutions, or foams) because they contain fewer potential irritants such as additives or preservatives [<a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/abstract/1,3,24\" class=\"abstract_t\">1,3,24</a>]. However, some patients prefer other vehicles because ointments make their hands too greasy for performing tasks.</p><p>The efficacy of topical corticosteroids versus placebo or no treatment for dyshidrotic eczema has not been adequately evaluated in randomized trials. However, they are used in clinical practice because of their antiinflammatory properties and their efficacy in other forms of hand eczema. (See <a href=\"topic.htm?path=treatment-of-atopic-dermatitis-eczema#H7\" class=\"medical medical_review\">&quot;Treatment of atopic dermatitis (eczema)&quot;, section on 'Topical corticosteroids'</a>.)</p><p>The long-term use of topical corticosteroids is limited by their side effects, which include skin atrophy, striae, and telangiectasia. (See <a href=\"topic.htm?path=general-principles-of-dermatologic-therapy-and-topical-corticosteroid-use#H16\" class=\"medical medical_review\">&quot;General principles of dermatologic therapy and topical corticosteroid use&quot;, section on 'Side effects'</a>.)</p><p class=\"headingAnchor\" id=\"H15309899\"><span class=\"h3\">Topical calcineurin inhibitors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We generally do not suggest topical calcineurin inhibitors as the first-line antiinflammatory treatment for dyshidrotic eczema. The antiinflammatory effect of topical calcineurin inhibitors is approximately equivalent to moderate potency topical corticosteroids [<a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/abstract/25\" class=\"abstract_t\">25</a>]. In addition, topical calcineurin inhibitors are more expensive than topical corticosteroids.</p><p>However, when patients <span class=\"nowrap\">and/or</span> clinicians prefer to avoid long-term use of topical corticosteroids for the treatment of mild to moderate dyshidrotic eczema (<a href=\"image.htm?imageKey=DERM%2F83053%7EDERM%2F83056%7EDERM%2F83010\" class=\"graphic graphic_picture graphicRef83053 graphicRef83056 graphicRef83010 \">picture 1D, 1F-G</a>), the topical calcineurin inhibitor <a href=\"topic.htm?path=tacrolimus-drug-information\" class=\"drug drug_general\">tacrolimus</a> is an alternative [<a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/abstract/26,27\" class=\"abstract_t\">26,27</a>]. Tacrolimus 0.1% ointment is applied twice daily until resolution.</p><p>In a randomized trial including 16 patients with moderate to severe dyshidrotic eczema, topical <a href=\"topic.htm?path=tacrolimus-drug-information\" class=\"drug drug_general\">tacrolimus</a> was compared with <a href=\"topic.htm?path=mometasone-drug-information\" class=\"drug drug_general\">mometasone</a> furoate, a high-potency (group three) topical corticosteroid [<a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/abstract/28\" class=\"abstract_t\">28</a>]. After four weeks of treatment with either topical tacrolimus 0.1% or mometasone furoate 0.1% ointment, the dyshidrotic eczema area and severity index (DASI) was reduced by more than 50 percent. </p><p class=\"headingAnchor\" id=\"H16212295\"><span class=\"h2\">Severe disease</span></p><p class=\"headingAnchor\" id=\"H15309876\"><span class=\"h3\">Systemic corticosteroids</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In addition to the general measures described above, we suggest oral rather than topical corticosteroids for the treatment of severe dyshidrotic eczema (<a href=\"image.htm?imageKey=DERM%2F83007%7EDERM%2F83006%7EDERM%2F83055\" class=\"graphic graphic_picture graphicRef83007 graphicRef83006 graphicRef83055 \">picture 2A-C</a>). (See <a href=\"#H20269116\" class=\"local\">'Assessment of severity'</a> above and <a href=\"#H16212203\" class=\"local\">'General measures'</a> above.)</p><p>We generally start with <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a> 40 to 60 mg once per day in the morning for one week. If there is an adequate response, the dose is then reduced by 50 percent in the next five to seven days and finally tapered and discontinued over the following two weeks. </p><p>Oral corticosteroids for dyshidrotic eczema have not been evaluated in clinical trials. However, in clinical experience they have been beneficial for the short-term treatment of dyshidrotic eczema and other forms of severe eczematous dermatitis. (See <a href=\"topic.htm?path=management-of-severe-atopic-dermatitis-eczema-in-children#H1275907174\" class=\"medical medical_review\">&quot;Management of severe atopic dermatitis (eczema) in children&quot;, section on 'Systemic corticosteroids'</a>.)</p><p class=\"headingAnchor\" id=\"H15309884\"><span class=\"h3\">Topical corticosteroids</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Superpotent topical corticosteroids (group one, (<a href=\"image.htm?imageKey=DERM%2F62402\" class=\"graphic graphic_table graphicRef62402 \">table 1</a>)) are a treatment option for severe dyshidrotic eczema in patients for whom systemic glucocorticoids are contraindicated or patients who prefer to avoid systemic corticosteroids. </p><p>Topical corticosteroids are applied twice daily for two to four weeks. Ointments generally are preferred to other vehicles (creams, solutions, or foams) because they contain fewer potential irritants such as additives or preservatives [<a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/abstract/1,3,24\" class=\"abstract_t\">1,3,24</a>]. However, some patients prefer other vehicles because ointments make their hands too greasy for performing tasks. </p><p>Application of topical corticosteroids under occlusive dressings (eg, polyethylene gloves for the hands or plastic wrap for the feet) may be helpful in patients with severe disease. Occlusive dressings enhance the corticosteroid penetration into the skin and may lead to a more rapid response. To limit the inconvenience of occlusive dressings, they are usually used at nighttime for three to seven days. However, some patients prefer open application of topical corticosteroids because they find occlusive dressings uncomfortable.</p><p>The risk of systemic absorption of topical corticosteroids applied on palms or soles is low because of the limited area involved and greater thickness of volar skin [<a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/abstract/29\" class=\"abstract_t\">29</a>]. However, a prolonged use of superpotent topical corticosteroids is associated with cutaneous side effects including skin atrophy, striae, and telangiectasia. (See <a href=\"topic.htm?path=general-principles-of-dermatologic-therapy-and-topical-corticosteroid-use#H16\" class=\"medical medical_review\">&quot;General principles of dermatologic therapy and topical corticosteroid use&quot;, section on 'Side effects'</a>.)</p><p class=\"headingAnchor\" id=\"H20269006\"><span class=\"h2\">Treatment response</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Clinical criteria to evaluate the response to treatment include cessation of vesiculation, clearance of preexisting vesicles, and reduction of erythema, pruritus, and pain. Resolution is usually associated with increased skin dryness and desquamation. Emollients can be liberally used multiple times per day to reduce dryness and scaling. </p><p>If there is no <span class=\"nowrap\">improvement/resolution</span> in two to four weeks, additional evaluation is necessary. (See <a href=\"#H16212520\" class=\"local\">'Refractory disease'</a> below.)</p><p class=\"headingAnchor\" id=\"H16212520\"><span class=\"h2\">Refractory disease</span></p><p class=\"headingAnchor\" id=\"H16212528\"><span class=\"h3\">Evaluation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with clinical features of dyshidrotic eczema who do not respond or are not adequately controlled after two to four weeks of topical or systemic corticosteroids or topical <a href=\"topic.htm?path=tacrolimus-drug-information\" class=\"drug drug_general\">tacrolimus</a> may need further evaluation to confirm or rule out the diagnosis. </p><p>Additional testing may include (see <a href=\"#H26544737\" class=\"local\">'Differential diagnosis'</a> above):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Potassium hydroxide (KOH) preparation to rule out a fungal infection.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Bacterial culture to rule out bacterial superinfection &ndash; Superinfection with <em>S. aureus</em> is a common cause of inadequate response to treatment in patients with hand eczema, especially with severe disease and wet, weeping lesions. Bacterial superinfection is treated with oral antibiotics. (See <a href=\"topic.htm?path=impetigo#H13\" class=\"medical medical_review\">&quot;Impetigo&quot;, section on 'Systemic antibiotics'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Skin biopsy and histopathologic examination to confirm the diagnosis of dyshidrotic eczema and exclude other conditions. Periodic acid-Schiff (PAS)&nbsp;staining for fungal elements should be included. (See <a href=\"#H26544729\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patch testing and detailed history of household- or work-related exposures to exclude an allergic or irritant contact dermatitis. (See <a href=\"topic.htm?path=patch-testing\" class=\"medical medical_review\">&quot;Patch testing&quot;</a> and <a href=\"topic.htm?path=clinical-features-and-diagnosis-of-allergic-contact-dermatitis#H111504337\" class=\"medical medical_review\">&quot;Clinical features and diagnosis of allergic contact dermatitis&quot;, section on 'History'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H16212550\"><span class=\"h3\">Treatment</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We suggest oral or topical psoralen plus ultraviolet A therapy (PUVA) for patients with confirmed diagnosis of dyshidrotic eczema who have frequent or severe episodes that are not adequately controlled with topical or systemic corticosteroids or topical <a href=\"topic.htm?path=tacrolimus-drug-information\" class=\"drug drug_general\">tacrolimus</a>.</p><p>The use of PUVA for patients with dyshidrotic eczema is largely supported by its use in the treatment of other inflammatory dermatoses, as only a few small clinical trials have demonstrated clinical improvement with PUVA in patients with dyshidrotic eczema [<a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/abstract/30-33\" class=\"abstract_t\">30-33</a>]. </p><p>Phototherapy may not be available in all communities. Phototherapy treatments are usually delivered two or three times per week. Several weeks of treatment are required to induce clinical improvement and several months are required for resolution. Thus, the potential benefits of phototherapy should be weighed against the inconvenience of prolonged therapy on a case by case basis. Phototherapy that is limited to the palms and soles has few adverse effects. (See <a href=\"topic.htm?path=psoralen-plus-ultraviolet-a-puva-photochemotherapy#H1941672\" class=\"medical medical_review\">&quot;Psoralen plus ultraviolet A (PUVA) photochemotherapy&quot;, section on 'Topical PUVA'</a>.) </p><p>Systemic immunosuppressive agents such as low-dose <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a>, <a href=\"topic.htm?path=mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information\" class=\"drug drug_general\">mycophenolate</a> mofetil, and cyclosporin, have been occasionally used in the management of patients with severe dyshidrotic eczema [<a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/abstract/34,35\" class=\"abstract_t\">34,35</a>]. Their use has not been evaluated in randomized trials and there is insufficient evidence of benefit to suggest their use in refractory cases. </p><p class=\"headingAnchor\" id=\"H26544941\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Acute palmoplantar eczema (also known as dyshidrotic eczema or pompholyx) is a recurrent, pruritic vesicular eruption affecting the palms, soles, or both. It occurs most commonly in young adults with equal frequency in males and females. (See <a href=\"#H26544681\" class=\"local\">'Introduction'</a> above and <a href=\"#H26544689\" class=\"local\">'Epidemiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Dyshidrotic eczema is characterized by the sudden eruption of intensely pruritic vesicles on the palms (<a href=\"image.htm?imageKey=DERM%2F82781\" class=\"graphic graphic_picture graphicRef82781 \">picture 1A</a>), soles, or lateral aspects of the fingers (<a href=\"image.htm?imageKey=DERM%2F112980\" class=\"graphic graphic_picture graphicRef112980 \">picture 1C</a>). The vesicles persist for several weeks, desiccate, and resolve with desquamation. Episodes may recur at intervals of three to four weeks for months or years. (See <a href=\"#H26544713\" class=\"local\">'Clinical presentation'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The diagnosis of dyshidrotic eczema is usually based upon the clinical appearance and location of lesions, symptoms, and history. In most patients, patch testing is useful to determine whether there is a component of allergic contact dermatitis. (See <a href=\"#H26544729\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The differential diagnosis of dyshidrotic eczema includes bullous tinea (<a href=\"image.htm?imageKey=DERM%2F82787\" class=\"graphic graphic_picture graphicRef82787 \">picture 5B</a>), dermatophytid reaction (<a href=\"image.htm?imageKey=DERM%2F52664\" class=\"graphic graphic_picture graphicRef52664 \">picture 8</a>), bullous impetigo, herpes simplex infection (<a href=\"image.htm?imageKey=ID%2F52029\" class=\"graphic graphic_picture graphicRef52029 \">picture 9</a>), allergic contact dermatitis (<a href=\"image.htm?imageKey=DERM%2F82993\" class=\"graphic graphic_picture graphicRef82993 \">picture 4A</a>), and palmoplantar pustulosis (<a href=\"image.htm?imageKey=DERM%2F62582%7EDERM%2F82843\" class=\"graphic graphic_picture graphicRef62582 graphicRef82843 \">picture 10A-B</a>). (See <a href=\"#H26544737\" class=\"local\">'Differential diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Avoidance of irritants or exacerbating factors is important for most patients with dyshidrotic eczema. (See <a href=\"#H16212203\" class=\"local\">'General measures'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with mild to moderate dyshidrotic eczema (<a href=\"image.htm?imageKey=DERM%2F82784%7EDERM%2F83056%7EDERM%2F83053%7EDERM%2F82781\" class=\"graphic graphic_picture graphicRef82784 graphicRef83056 graphicRef83053 graphicRef82781 \">picture 1A, 1D-F</a>) that has not responded to general measures, we suggest super high potency or high potency topical corticosteroids (group one to three (<a href=\"image.htm?imageKey=DERM%2F62402\" class=\"graphic graphic_table graphicRef62402 \">table 1</a>)) rather than calcineurin inhibitors (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). Topical corticosteroids are applied twice daily for two to four weeks. Ointments are preferred to other vehicles. (See <a href=\"#H15309892\" class=\"local\">'Topical corticosteroids'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We suggest oral corticosteroids for the treatment of severe dyshidrotic eczema (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). For patients in whom oral corticosteroids are contraindicated or who prefer to avoid systemic corticosteroids, superpotent topical corticosteroids (group one, (<a href=\"image.htm?imageKey=DERM%2F62402\" class=\"graphic graphic_table graphicRef62402 \">table 1</a>)) are an alternative. Treatment is started with <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a> 40 to 60 mg per day for one week. The dose may be reduced by 50 percent in the next five to seven days and then tapered and discontinued over the following two weeks. (See <a href=\"#H15309876\" class=\"local\">'Systemic corticosteroids'</a> above and <a href=\"#H15309884\" class=\"local\">'Topical corticosteroids'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with clinical features of dyshidrotic eczema who do not respond or are not adequately controlled after two to four weeks of topical or systemic corticosteroids may need further evaluation to confirm or rule out the diagnosis. (See <a href=\"#H16212528\" class=\"local\">'Evaluation'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We suggest phototherapy with oral or topical psoralen plus ultraviolet A (PUVA) for patients with confirmed diagnosis of dyshidrotic eczema who have frequent or severe episodes that are not adequately controlled with topical or systemic corticosteroids or topical <a href=\"topic.htm?path=tacrolimus-drug-information\" class=\"drug drug_general\">tacrolimus</a> (<a href=\"grade.htm?i=5\" class=\"grade\">Grade 2B</a>). (See <a href=\"#H16212520\" class=\"local\">'Refractory disease'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/abstract/1\" class=\"nounderline abstract_t\">Veien NK. Acute and recurrent vesicular hand dermatitis. Dermatol Clin 2009; 27:337.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/abstract/2\" class=\"nounderline abstract_t\">Wollina U. Pompholyx: a review of clinical features, differential diagnosis, and management. Am J Clin Dermatol 2010; 11:305.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/abstract/3\" class=\"nounderline abstract_t\">Lofgren SM, Warshaw EM. Dyshidrosis: epidemiology, clinical characteristics, and therapy. Dermatitis 2006; 17:165.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/abstract/4\" class=\"nounderline abstract_t\">SHELLEY WB. Dysidrosis (pompholyx). AMA Arch Derm Syphilol 1953; 68:314.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/abstract/5\" class=\"nounderline abstract_t\">Kutzner H, Wurzel RM, Wolff HH. Are acrosyringia involved in the pathogenesis of &quot;dyshidrosis&quot;? Am J Dermatopathol 1986; 8:109.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/abstract/6\" class=\"nounderline abstract_t\">Meding B, Swanbeck G. Epidemiology of different types of hand eczema in an industrial city. Acta Derm Venereol 1989; 69:227.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/abstract/7\" class=\"nounderline abstract_t\">Agner T, Aalto-Korte K, Andersen KE, et al. Classification of hand eczema. J Eur Acad Dermatol Venereol 2015; 29:2417.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/abstract/8\" class=\"nounderline abstract_t\">de Boer EM, Bruynzeel DP, van Ketel WG. Dyshidrotic eczema as an occupational dermatitis in metal workers. Contact Dermatitis 1988; 19:184.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/abstract/9\" class=\"nounderline abstract_t\">Jain VK, Aggarwal K, Passi S, Gupta S. Role of contact allergens in pompholyx. J Dermatol 2004; 31:188.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/abstract/10\" class=\"nounderline abstract_t\">Lodi A, Betti R, Chiarelli G, et al. Epidemiological, clinical and allergological observations on pompholyx. Contact Dermatitis 1992; 26:17.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/abstract/11\" class=\"nounderline abstract_t\">Chen JJ, Liang YH, Zhou FS, et al. The gene for a rare autosomal dominant form of pompholyx maps to chromosome 18q22.1-18q22.3. J Invest Dermatol 2006; 126:300.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/abstract/12\" class=\"nounderline abstract_t\">Pitch&eacute; P, Boukari M, Tchangai-Walla K. [Factors associated with palmoplantar or plantar pompholyx: a case-control study]. Ann Dermatol Venereol 2006; 133:139.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/abstract/13\" class=\"nounderline abstract_t\">Guillet MH, Wierzbicka E, Guillet S, et al. A 3-year causative study of pompholyx in 120 patients. Arch Dermatol 2007; 143:1504.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/abstract/14\" class=\"nounderline abstract_t\">Veien NK, Hattel T, Justesen O, N&oslash;rholm A. Oral challenge with metal salts. (I). Vesicular patch-test-negative hand eczema. Contact Dermatitis 1983; 9:402.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/abstract/15\" class=\"nounderline abstract_t\">Lehucher-Michel MP, Koeppel MC, Lanteaume A, Sayag J. Dyshidrotic eczema and occupation: a descriptive study. Contact Dermatitis 2000; 43:200.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/abstract/16\" class=\"nounderline abstract_t\">Uyttendaele H, Obadiah J, Grossman M. Dyshidrotic-like spongiotic dermatitis after intravenous immunoglobulin therapy. J Drugs Dermatol 2003; 2:337.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/abstract/17\" class=\"nounderline abstract_t\">Iannaccone S, Sferrazza B, Quattrini A, et al. Pompholyx (vesicular eczema) after i.v. immunoglobulin therapy for neurologic disease. Neurology 1999; 53:1154.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/abstract/18\" class=\"nounderline abstract_t\">Gerstenblith MR, Antony AK, Junkins-Hopkins JM, Abuav R. Pompholyx and eczematous reactions associated with intravenous immunoglobulin therapy. J Am Acad Dermatol 2012; 66:312.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/abstract/19\" class=\"nounderline abstract_t\">Shiraishi T, Yamamoto T. Severe dyshidrotic eczema after intravenous immunoglobulin therapy for Kawasaki syndrome. Pediatr Dermatol 2013; 30:e30.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/abstract/20\" class=\"nounderline abstract_t\">Douwes KE, Karrer S, Abels C, et al. Does smoking influence the efficacy of bath-PUVA therapy in chronic palmoplantar eczema? Photodermatol Photoimmunol Photomed 2000; 16:25.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/abstract/21\" class=\"nounderline abstract_t\">Man I, Ibbotson SH, Ferguson J. Photoinduced pompholyx: a report of 5 cases. J Am Acad Dermatol 2004; 50:55.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/abstract/22\" class=\"nounderline abstract_t\">Hald M, Agner T, Blands J, et al. Clinical severity and prognosis of hand eczema. Br J Dermatol 2009; 160:1229.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/abstract/23\" class=\"nounderline abstract_t\">Vocks E, Pl&ouml;tz SG, Ring J. The Dyshidrotic Eczema Area and Severity Index - A score developed for the assessment of dyshidrotic eczema. Dermatology 1999; 198:265.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/abstract/24\" class=\"nounderline abstract_t\">Warshaw EM. Therapeutic options for chronic hand dermatitis. Dermatol Ther 2004; 17:240.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/abstract/25\" class=\"nounderline abstract_t\">Ashcroft DM, Dimmock P, Garside R, et al. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials. BMJ 2005; 330:516.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/abstract/26\" class=\"nounderline abstract_t\">Belsito DV, Fowler JF Jr, Marks JG Jr, et al. Pimecrolimus cream 1%: a potential new treatment for chronic hand dermatitis. Cutis 2004; 73:31.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/abstract/27\" class=\"nounderline abstract_t\">Thelmo MC, Lang W, Brooke E, et al. An open-label pilot study to evaluate the safety and efficacy of topically applied tacrolimus ointment for the treatment of hand and/or foot eczema. J Dermatolog Treat 2003; 14:136.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/abstract/28\" class=\"nounderline abstract_t\">Schnopp C, Remling R, M&ouml;hrenschlager M, et al. Topical tacrolimus (FK506) and mometasone furoate in treatment of dyshidrotic palmar eczema: a randomized, observer-blinded trial. J Am Acad Dermatol 2002; 46:73.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/abstract/29\" class=\"nounderline abstract_t\">Pariser D. Topical corticosteroids and topical calcineurin inhibitors in the treatment of atopic dermatitis: focus on percutaneous absorption. Am J Ther 2009; 16:264.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/abstract/30\" class=\"nounderline abstract_t\">Tzaneva S, Kittler H, Thallinger C, et al. Oral vs. bath PUVA using 8-methoxypsoralen for chronic palmoplantar eczema. Photodermatol Photoimmunol Photomed 2009; 25:101.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/abstract/31\" class=\"nounderline abstract_t\">Polderman MC, Govaert JC, le Cessie S, Pavel S. A double-blind placebo-controlled trial of UVA-1 in the treatment of dyshidrotic eczema. Clin Exp Dermatol 2003; 28:584.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/abstract/32\" class=\"nounderline abstract_t\">Sezer E, Etikan I. Local narrowband UVB phototherapy vs. local PUVA in the treatment of chronic hand eczema. Photodermatol Photoimmunol Photomed 2007; 23:10.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/abstract/33\" class=\"nounderline abstract_t\">Petering H, Breuer C, Herbst R, et al. Comparison of localized high-dose UVA1 irradiation versus topical cream psoralen-UVA for treatment of chronic vesicular dyshidrotic eczema. J Am Acad Dermatol 2004; 50:68.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/abstract/34\" class=\"nounderline abstract_t\">Egan CA, Rallis TM, Meadows KP, Krueger GG. Low-dose oral methotrexate treatment for recalcitrant palmoplantar pompholyx. J Am Acad Dermatol 1999; 40:612.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-palmoplantar-eczema-dyshidrotic-eczema/abstract/35\" class=\"nounderline abstract_t\">Granlund H, Erkko P, Eriksson E, Reitamo S. Comparison of cyclosporine and topical betamethasone-17,21-dipropionate in the treatment of severe chronic hand eczema. Acta Derm Venereol 1996; 76:371.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 13657 Version 9.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H26544941\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H26544681\" id=\"outline-link-H26544681\">INTRODUCTION</a></li><li><a href=\"#H26006232\" id=\"outline-link-H26006232\">TERMINOLOGY</a></li><li><a href=\"#H26544689\" id=\"outline-link-H26544689\">EPIDEMIOLOGY</a></li><li><a href=\"#H26544705\" id=\"outline-link-H26544705\">ETIOLOGY AND PATHOGENESIS</a></li><li><a href=\"#H26544713\" id=\"outline-link-H26544713\">CLINICAL PRESENTATION</a></li><li><a href=\"#H26544729\" id=\"outline-link-H26544729\">DIAGNOSIS</a><ul><li><a href=\"#H18792269\" id=\"outline-link-H18792269\">Clinical diagnosis</a></li><li><a href=\"#H18792277\" id=\"outline-link-H18792277\">Histopathology</a></li><li><a href=\"#H18792310\" id=\"outline-link-H18792310\">Patch testing</a></li></ul></li><li><a href=\"#H26544737\" id=\"outline-link-H26544737\">DIFFERENTIAL DIAGNOSIS</a></li><li><a href=\"#H20269882\" id=\"outline-link-H20269882\">CLINICAL COURSE</a></li><li><a href=\"#H26544808\" id=\"outline-link-H26544808\">MANAGEMENT</a><ul><li><a href=\"#H20269116\" id=\"outline-link-H20269116\">Assessment of severity</a></li><li><a href=\"#H16212203\" id=\"outline-link-H16212203\">General measures</a></li><li><a href=\"#H16212111\" id=\"outline-link-H16212111\">Mild to moderate disease</a><ul><li><a href=\"#H15309892\" id=\"outline-link-H15309892\">- Topical corticosteroids</a></li><li><a href=\"#H15309899\" id=\"outline-link-H15309899\">- Topical calcineurin inhibitors</a></li></ul></li><li><a href=\"#H16212295\" id=\"outline-link-H16212295\">Severe disease</a><ul><li><a href=\"#H15309876\" id=\"outline-link-H15309876\">- Systemic corticosteroids</a></li><li><a href=\"#H15309884\" id=\"outline-link-H15309884\">- Topical corticosteroids</a></li></ul></li><li><a href=\"#H20269006\" id=\"outline-link-H20269006\">Treatment response</a></li><li><a href=\"#H16212520\" id=\"outline-link-H16212520\">Refractory disease</a><ul><li><a href=\"#H16212528\" id=\"outline-link-H16212528\">- Evaluation</a></li><li><a href=\"#H16212550\" id=\"outline-link-H16212550\">- Treatment</a></li></ul></li></ul></li><li><a href=\"#H26544941\" id=\"outline-link-H26544941\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DERM/13657|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=DERM/83056\" class=\"graphic graphic_picture\">- Dyshidrotic eczema moderate</a></li><li><a href=\"image.htm?imageKey=DERM/112980\" class=\"graphic graphic_picture\">- Dyshidrotic eczema acute fingers</a></li><li><a href=\"image.htm?imageKey=DERM/82781\" class=\"graphic graphic_picture\">- Dyshidrotic eczema mild 2</a></li><li><a href=\"image.htm?imageKey=DERM/82783\" class=\"graphic graphic_picture\">- Dyshidrotic eczema fingers</a></li><li><a href=\"image.htm?imageKey=DERM/83007\" class=\"graphic graphic_picture\">- Dyshidrotic eczema large bullae</a></li><li><a href=\"image.htm?imageKey=DERM/83006\" class=\"graphic graphic_picture\">- Dyshidrotic eczema severe</a></li><li><a href=\"image.htm?imageKey=DERM/82782\" class=\"graphic graphic_picture\">- Dyshidrotic eczema foot 2</a></li><li><a href=\"image.htm?imageKey=DERM/82784\" class=\"graphic graphic_picture\">- Dyshidrotic eczema nail dystrophy</a></li><li><a href=\"image.htm?imageKey=DERM/83010\" class=\"graphic graphic_picture\">- Dyshidrotic eczema mild</a></li><li><a href=\"image.htm?imageKey=DERM/82993\" class=\"graphic graphic_picture\">- Allergic contact dermatitis hand</a></li><li><a href=\"image.htm?imageKey=DERM/83192\" class=\"graphic graphic_picture\">- Allergic contact dermatitis interdigital</a></li><li><a href=\"image.htm?imageKey=PC/54214\" class=\"graphic graphic_picture\">- Acute tinea pedis</a></li><li><a href=\"image.htm?imageKey=DERM/82787\" class=\"graphic graphic_picture\">- Tinea pedis bullous</a></li><li><a href=\"image.htm?imageKey=DERM/50299\" class=\"graphic graphic_picture\">- Chronic irritant contact dermatitis</a></li><li><a href=\"image.htm?imageKey=DERM/59959\" class=\"graphic graphic_picture\">- Chronic irritant contact dermatitis 2</a></li><li><a href=\"image.htm?imageKey=DERM/82881\" class=\"graphic graphic_picture\">- Atopic dermatitis hand</a></li><li><a href=\"image.htm?imageKey=DERM/52664\" class=\"graphic graphic_picture\">- Autoeczematization on hand</a></li><li><a href=\"image.htm?imageKey=ID/52029\" class=\"graphic graphic_picture\">- Herpetic whitlow finger</a></li><li><a href=\"image.htm?imageKey=DERM/62582\" class=\"graphic graphic_picture\">- Palmoplantar pustulosis - heel</a></li><li><a href=\"image.htm?imageKey=DERM/82843\" class=\"graphic graphic_picture\">- Palmoplantar pustulosis hands</a></li><li><a href=\"image.htm?imageKey=DERM/82842\" class=\"graphic graphic_picture\">- Palmoplantar pustulosis old lesions</a></li><li><a href=\"image.htm?imageKey=DERM/50357\" class=\"graphic graphic_picture\">- Dyshidrosiform bullous pemphigoid</a></li><li><a href=\"image.htm?imageKey=DERM/83053\" class=\"graphic graphic_picture\">- Dyshidrotic eczema mild 3</a></li><li><a href=\"image.htm?imageKey=DERM/83055\" class=\"graphic graphic_picture\">- Dyshidrotic eczema severe 2</a></li></ul></li><li><div id=\"DERM/13657|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DERM/62402\" class=\"graphic graphic_table\">- Topical corticosteroids</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=atopic-dermatitis-eczema-pathogenesis-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Atopic dermatitis (eczema): Pathogenesis, clinical manifestations, and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-features-and-diagnosis-of-allergic-contact-dermatitis\" class=\"medical medical_review\">Clinical features and diagnosis of allergic contact dermatitis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-features-and-diagnosis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid\" class=\"medical medical_review\">Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-herpes-simplex-virus-type-1-infection\" class=\"medical medical_review\">Clinical manifestations and diagnosis of herpes simplex virus type 1 infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=dermatophyte-tinea-infections\" class=\"medical medical_review\">Dermatophyte (tinea) infections</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=general-principles-of-dermatologic-therapy-and-topical-corticosteroid-use\" class=\"medical medical_review\">General principles of dermatologic therapy and topical corticosteroid use</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=impetigo\" class=\"medical medical_review\">Impetigo</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=irritant-contact-dermatitis-in-adults\" class=\"medical medical_review\">Irritant contact dermatitis in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-allergic-contact-dermatitis\" class=\"medical medical_review\">Management of allergic contact dermatitis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-severe-atopic-dermatitis-eczema-in-children\" class=\"medical medical_review\">Management of severe atopic dermatitis (eczema) in children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=neutrophilic-dermatoses\" class=\"medical medical_review\">Neutrophilic dermatoses</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=patch-testing\" class=\"medical medical_review\">Patch testing</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathogenesis-clinical-manifestations-and-diagnosis-of-pemphigus\" class=\"medical medical_review\">Pathogenesis, clinical manifestations, and diagnosis of pemphigus</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=psoralen-plus-ultraviolet-a-puva-photochemotherapy\" class=\"medical medical_review\">Psoralen plus ultraviolet A (PUVA) photochemotherapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-atopic-dermatitis-eczema\" class=\"medical medical_review\">Treatment of atopic dermatitis (eczema)</a></li></ul></div></div>","javascript":null}